Valerio Therapeutics (XPAR:ALVIO) Dividends per Share : €0.00 (TTM As of Jun. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Valerio Therapeutics Dividends per Share?

Valerio Therapeutics's dividends per share for the six months ended in Jun. 2024 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00. Its Dividend Payout Ratio for the six months ended in Jun. 2024 was 0.00. As of today, Valerio Therapeutics's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Valerio Therapeutics Dividends per Share Historical Data

The historical data trend for Valerio Therapeutics's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valerio Therapeutics Dividends per Share Chart

Valerio Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividends per Share

Get a 7-Day Free Trial

Valerio Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Valerio Therapeutics's Dividends per Share

For the Biotechnology subindustry, Valerio Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valerio Therapeutics's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valerio Therapeutics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Valerio Therapeutics's Dividend Yield % falls into.

Valerio Therapeutics Dividends per Share Calculation

Dividends paid to per common share.

Valerio Therapeutics (XPAR:ALVIO) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Valerio Therapeutics's Dividend Payout Ratio for the quarter that ended in Jun. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2024 )	/	EPS without NRI (Q: Jun. 2024 )
	=	0	/	-0.07
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Valerio Therapeutics Dividends per Share Related Terms

Thank you for viewing the detailed overview of Valerio Therapeutics's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Valerio Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valerio Therapeutics (XPAR:ALVIO) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

C4X:Germany

Address

49 Boulevard du General, Martial Valin, Paris, FRA, 75015

Website

https://www.valeriotx.com

Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.

Valerio Therapeutics Headlines

No Headlines